Constitutively Active CCR5 Chemokine Receptors Differ in Mediating HIV Envelope-dependent Fusion

Alex de Voux1ª, Mei-Chi Chan1, Asongna T. Folefoc1,b, Michael T. Madziva2, Colleen A. Flanagan2*

Medical Research Council Receptor Biology Research Unit, Division of Medical Biochemistry, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa, 2 Medical Research Council Receptor Biology Research Unit, School of Physiology, University of the Witwatersrand, Johannesburg, South Africa

Abstract

The CCR5 chemokine receptor is a rhodopsin-like G protein-coupled receptor that mediates the effects of pro-inflammatory β-chemokines. CCR5 is also the major co-receptor for entry of human immunodeficiency virus (HIV) into human cells. G protein-coupled receptors exist in ensembles of active and inactive conformations. Active receptor conformations can be stabilized by mutations. Although binding of the HIV envelope protein to CCR5 stimulates cellular signaling, the CCR5 conformation that induces fusion of the viral membrane with cellular membranes is not known. We mutated conserved amino acids to generate constitutively active CCR5 receptors, which are stabilized in active conformations, and tested the ability of constitutively active CCR5 receptors to mediate HIV envelope-directed membrane fusion. Mutation of the Asp2.59(125) and Arg6.32(225) residues of CCR5 did not cause constitutive activity, but Lys or Pro substitutions for Thr2.56(82), in the TxP motif, caused high basal inositol phosphate signaling. Signaling did not increase in response to MIP-1b, suggesting that the Thr2.56(82) mutants were fully stabilized in active conformations. The Thr2.56(82)Lys mutation severely decreased cell surface CCR5 expression. Combining the Thr2.56(82)Lys mutation with an Arg6.32(225)Gln mutation partially reversed the decrease in expression. Mutants with the Thr2.56(82)Lys substitutions were poor mediators of HIV envelope-directed membrane fusion, but mutants with the Thr65(82)Pro substitution exhibited full co-receptor function. Our results suggest that the Thr65(82)Lys and Thr2.65(82)Pro mutations stabilize distinct constitutively active CCR5 conformations. Lys in position 2.65(82) stabilizes activated receptor conformations that appear to be constitutively internalized and do not induce envelope-dependent membrane fusion, whereas Pro stabilizes activated conformations that are not constitutively internalized and fully mediate envelope-directed membrane fusion.

Introduction

The CCR5 chemokine receptor is a G protein-coupled receptor (GPCR) that mediates leukocyte chemotaxis and recruitment to sites of inflammation in response to pro-inflammatory β-chemokines, including macrophage inflammatory protein 1β (MIP-1β, CCL4) [1,2]. CCR5 is also the major co-receptor for human immunodeficiency virus (HIV) infection. Sequential binding of the surface gp120 subunit of the HIV envelope glycoprotein (Env) to cellular CD4 and CCR5 induces a “fusogenic” Env conformation that penetrates the cell membrane and fuses the viral and cellular membranes. The CCR5 chemokine receptor is an attractive target for treatment and prevention of HIV infection and the first CCR5-blocking drug, maraviroc, was approved in 2007.

GPCR proteins exist in ensembles of inactive conformations, which are stabilized by inverse agonists and do not support intracellular signaling, and active receptor conformations, which are stabilized by agonists and activate corresponding ensembles of cellular signaling pathways. Ligands may selectively stabilize ensembles of receptor conformations that activate subsets of cellular signaling pathways [3,4]. For example, chemokines stabilize CCR5 receptor conformations that activate G protein signaling and conformations that are recognized by G protein-coupled receptor kinases and arrestins, which promote receptor internalization. Some chemokine ligands have distinct efficacies for stimulating intracellular signaling and internalization of CCR5 [5]. HIV binding to CCR5 must stabilize a receptor conformation that induces the fusion conformation of Env. HIV also stimulates CCR5-dependent cellular signaling [6,7,8].

The structures of a small number of GPCR proteins have been determined in inverse agonist-bound inactive conformations [9,10,11,12] and in complexes with agonist and a G protein or G protein mimetic, which stabilize active receptor conformations [13,14,15]. The crystal structures support hypotheses that amino acids that are highly conserved among GPCRs form distinct intramolecular interactions in active and inactive receptor conformations and act as activation “switches” [4,16,17,18].
Supporting the switch hypothesis, mutation of the Asp³.49 and Arg⁶.32 residues of the conserved DRY (Asp–Arg–Tyr) motif, in transmembrane segment (TMS) 3, stabilizes mutant receptors in activated conformations, which stimulate cellular signaling in the absence of agonist [19]. Different mutations of the Thr².56(82) and Pro².58(84) residues of the conserved TxP motif, stabilized CCR5 mutants in inactive [20] or constitutively active conformations [21]. A naturally-occurring Arg³.32/22(23)Gln mutation causes partial constitutive activity in CCR5 [22].

The CCR5 conformation(s) that induce the fusogenic changes in Env are not known. Binding of the gp120 subunit of Env to CCR5 stimulates intracellular signaling [6,7,8], suggesting that HIV stabilizes activated CCR5 conformations that activate G proteins and other cytosolic signaling proteins. On the other hand, CCR5 receptors with inactivating mutations, which uncouple CCR5 from activation of G protein and other signaling pathways, mediated Env-dependent membrane fusion [23,24,25], suggesting that inactive CCR5 conformations mediate HIV entry. Small molecule CCR5-binding anti-HIV drugs are inverse agonists. HIV strains that are resistant to CCR5 “blockers” use drug-bound CCR5 to infect cells [26,27,28,29], suggesting that inactive CCR5 conformations mediate HIV infection. We have hypothesized that activated conformations that stimulate G protein signaling would be poor mediators of Env-directed membrane fusion.

We have investigated the ability of activated conformations of CCR5 to mediate Env-directed membrane fusion by mutating conserved “switch” residues of the human CCR5 chemokine receptor. Mutation of Asp³.49/125 and Arg⁶.32/22(23) did not increase constitutive activity. CCR5 mutants with Pro or Lys substituted for Thr².56(82) showed high basal cellular signaling, which was not increased by stimulation with MIP-1β. The Thr².56(82)Lys mutation decreased cell surface CCR5 protein, whereas the Thr².56(82)Pro mutation did not. Constitutively active CCR5 receptors differed in their ability to mediate Env-directed membrane fusion. Our results suggest that Pro and Lys substitutions in position 2.56(82) stabilize distinct activated CCR5 conformations that differ in their localization at the cell surface and in their ability to induce HIV Env-dependent membrane fusion.

**Materials and Methods**

**DNA Constructs, Cell Lines and Proteins**

The chimeric G protein construct, G26qi, which allows receptors that usually activate the Gi/o family of G proteins to stimulate inositol phosphate (IP) signaling [30] was prepared by site-directed mutagenesis, cloned into the pcDNA3.1(+) expression vector (Invitrogen, Carlsbad, CA) and stably expressed in HEK 293 cells (HEK-Gqi) as previously described [22]. The HIV-1C env construct pThr.gp150CT [31] was a gift from Carolyn Williams (University of Cape Town). The codon-optimized, carboxy-terminally truncated Du151 env, Du151 gp150, was subcloned into the pcDNA3.1(+) expression vector (Invitrogen). The HIV-1 tat (GenBank Accession number X07861) cloned into pcDNA3.1, HIV-1 rev (GenBank Accession No. M34378) cloned into pcDNA3.1/Hygro (Invitrogen) and the pHIV-1LTR-Luc reporter construct [32] were gifts from Steven Jenkinson, GlaxoSmithKline. The following cell lines were obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: Human osteosarcoma cells stably expressing CD4 (HOS-CD4.pBabe-puro) or CD4 and CCR5 (HOS-CD4-CCR5) from Dr Nathaniel Landau [33]. The pHIV-1LTR-Luc construct was stably transfected into both of these cell lines. Recombinant human chemokine MIP-1β (CCL4) was purchased from Peprotec (Rocky Hill, NJ).

**Generation of Mutant CCR5 Receptor Constructs**

Mutant CCR5 receptor constructs were generated by PCR using Deep Vent high fidelity DNA polymerase (New England Biolabs, Ipswich, MA) and the wild type human CCR5 chemokine receptor cDNA, cloned into the pcDNA3.1(+) expression vector (Invitrogen, Carlsbad, CA), as template. The Ballesteros and Weinstein amino acid numbering system [34] is used to facilitate comparison of CCR5 with other rhodopsin-like GPCRs. The generic residue number consists of the TMS, 1 to 7, in which the residue is located, followed by the position relative to the most conserved residue of the TMS, which is designated number 50. The generic number is followed by the number of the residue in the sequence of the CCR5 receptor. For example, the Asp³.49/125 residue in the conserved DRY motif of the CCR5 receptor is designated Asp³.49/125, because it immediately precedes the most conserved residue in TMS5, Arg⁵.30/126. Asp³.49/125 was mutated to Ala (Asp³.49/125Ala) and Asn (Asp³.49/125Asn), whereas the Thr².56(82) residue in TMS2 of CCR5 was mutated to Pro (Thr².56(82)Pro), Lys (Thr².56(82)Lys) and Arg (Thr².56(82)Arg) and Arg³.32/22(23) in the third intracellular loop, was mutated to Gln, Ala, Asp and Ghu. The Arg³.32/22(23)Gln construct was used as the template for the double mutants, Thr².56(82)Lys/Arg³.32/22(23)Gln and Thr².56(82)Pro/Arg³.32/22(23)Gln. Mutant constructs were sequenced and subcloned into the pcDNA3.1(+) and pcDNA3.1 Hygro(+) expression vectors.

**Cell Culture and Transfection**

HEK 293 cells (ATCC) were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, Invitrogen, Paisley, Scotland) containing fetal bovine serum (FBS, 10%, Highveld Biologicals, Johannesburg, South Africa) and cultured at 37°C with 10% CO₂. HEK-Gqi cells were maintained in DMEM supplemented with FBS (10%) and G418 (200 μg/ml). HOS-CD4.pBabe-puro and HOS-CD4-CCR5 cells were maintained in DMEM supplemented with FBS (10%) and puromycin (1 μg/ml), whereas the same cell lines stably transfected with pHIV-1LTR-Luc to generate the cell lines, HOS-CD4-Luc and HOS-CD4-CCR5-Luc, were maintained with FBS, puromycin (1 μg/ml) and G418 (400 μg/ml).

Cells were plated into 10 cm² dishes (3–6×10⁵ cells, Corning, Cambridge, USA) in a final volume of 10 ml DMEM with FBS (10%) 24 h before transfection. DNA constructs (6 μg) were incubated with FuGene HD (30 μl, Roche Diagnostics Corp., Indianapolis, USA) in serum-free DMEM (room temperature, 30 min) and added directly to the 10 ml medium in the 10 cm² dishes. Cells were incubated overnight (37°C; 5% CO₂). For stable transfections, selection antibiotics were added two days later and individual colonies of antibiotic-resistant cells were harvested and propagated. Attempts to stably transfect CCR5 constructs into HOS-CD4-Luc cells were unsuccessful. HOS-CD4-Luc cells transiently transfected with wild type and mutant CCR5 constructs were cultured in the presence of hygromycin B (200 μg/ml) for two days to increase the proportion of receptor-expressing cells and thus compensate for low transfection efficiency.

**IP Production**

Basal and MIP-1β-stimulation of IP second messenger production was assessed as previously described [22,35]. Briefly, HEK-Gqi cells (3×10⁶ per 10 cm dish) were transfected with wild type and
or mutant CCR5 receptor constructs, were distributed into 12-well plates (Corning, 2 plates/10 cm dish), incubated overnight and then incubated with [3H]inositol ([1 μCi/ml, Amersham Life Sciences, Buckinghamshire, England, 16–18 h). The resulting radio-labeled cells were pre-incubated with buffer I (40 mM NaCl, 4 mM KCl, 20 mM HEPES, 0.5 mM glucose, 1 mM CaCl2, 1 mM MgCl2, 10 mM LiCl, 0.1% BSA, 0.4% phenol red, 15 min, 37°C) and then incubated in duplicate with buffer I containing various concentrations of MIP-1β (0–10−7 M, 60 min, 37°C), after which the medium was replaced with pre-cooled formic acid (1 ml, 10 mM, 30 min, 4°C). The resulting cell lysates were applied to ion exchange columns (DOWEX-1, Sigma, Bellefonte, USA) and [3H]IP was eluted (1 M ammonium formate, 0.1 M formic acid) into vials containing scintillation fluid (16 ml, Quicksafe; Zinsser Analytical, Frankfurt, Germany) and counted. MIP-1β concentrations that stimulated half-maximal IP production (EC50 values) were calculated using GraphPad Prism and statistical significance was assessed using unpaired T-tests (GraphPad Prism).

Chemokine Competition Binding

MIP-1β was radio-i iodinated using the chloramine T method as previously described [36,37]. HEK 293 cells (3×106/10 cm dish), transiently transfected with wild type or mutant CCR5 receptor constructs were detached (5 mM EDTA, 50 mM HEPES, pH 7.4, 100 mM NaCl), re-suspended (3×105 cells/tube) in binding buffer (50 mM HEPES, pH 7.4, 1 mM CaCl2, 5 mM MgCl2, 0.5% BSA) and incubated, in triplicate, with 125I]-MIP-1β (50 000 cpm, approximately 0.3 pmol) and increasing concentrations of unlabeled MIP-1β (0 to 10−7 M) in a total volume of 0.2 ml (60 min, 27°C), as previously described [22,37]. Bound tracer was separated by filtration through glass-fiber filters (GF/C, Whatman, Maidstone, England) presoaked in 1% BSA. Filters were washed twice with washing buffer (50 mM HEPES, pH 7.4, 1 mM CaCl2, 5 mM MgCl2 and 0.5 M NaCl) and radioactivity was counted in a γ-counter. Total binding (B0) of 125I]-MIP-1β to the receptor was determined in the absence of unlabeled ligand, whereas non-specific binding (NSB) was determined as the amount of radiolabeled ligand bound in the presence of 10−7 M unlabeled MIP-1β or bound to untransfected cells. Specific binding of 125I]-MIP-1β was calculated as the difference between B0 and NSB. Concentrations of MIP-1β that displaced 50% of total specific 125I]-MIP-1β binding (IC50 values) were calculated using GraphPad Prism and nonlinear regression for one-site competition curves.

Fluorescence-Activated Cell Sorting (FACS) Analysis of CCR5 Receptor Expression

HEK 293 or HOS-CDC4-Luc cells transfected with wild type or mutant CCR5 constructs were detached from the 10 cm2 dishes, suspended in 10 ml of phosphate-buffered saline containing BSA (PBS-BSA, 137 mM NaCl, 2.7 mM KCl, 1.4 mM KH2PO4 and 4.3 mM Na2HPO4·7H2O, pH 7.3, 0.5% BSA) and centrifuged (1000 rpm, 10 min). The cell pellet was re-suspended in PBS-BSA (0.5 ml) and re-suspended cells (20 μl) were incubated with phycoerythrin-labeled 2D7 mouse anti-hCCR5 antibody (PE-2D7, BD Biosciences Pharmingen, Franklin Lakes, NJ, 50 ng, 21°C, 60 min) in the dark. Samples were centrifuged (2000 rpm, 10 min), washed in PBS-BSA (1.5 ml) and re-suspended in PBS-BSA (500 μl) for FACS analysis using a FACScalibur flow cytometer (Becton-Dickinson, Franklin Lakes, NJ). Untransfected HEK 293 cells stained with PE-2D7 were used as a negative control to set the gating threshold and the mean fluorescence of gated cells transfected with the wild type construct was defined as 100% for each experiment.

Env-Directed Cell Fusion Assay

A cell fusion assay that models the interaction of the host cell receptors with the Env protein expressed on the membrane of the HIV-1 virion [32] was used to assess the ability of mutant receptors to mediate Env-dependent membrane fusion. In this assay, HEK 293 cells expressing HIV Env protein and the HIV transcription factor, Tat, were mixed with HOS-CDC4-Luc reporter cells expressing CCR5 receptors. Binding of Env on the HEK 293 cells to CD4 and CCR5 on the transfected HOS-CDC4-Luc cells allows fusion of the cells and Tat expressed in HEK 293 cells is able to activate Luc expression via the LTR promoter in the HOS-CDC4-Luc cells. HOS-CDC4-Luc cells were transiently transfected with wild type or mutant CCR5 receptor cDNA cloned into the hygro mycin resistant vector, pCDNA3.1/Hygro(+)/ (Invitrogen), cultured overnight and then cultured (48 h) in DMEM supplemented with FCS (10%), G418 (400 μg/ml) and hygromycin (200 μg/ml, Sigma, St. Louis, Missouri) to select for transfected cells. Expression of CCR5 was assessed by FACS analysis and HOS-CDC4-Luc cells expressing wild type or mutant CCR5 constructs were seeded into 96-well plates (Corning, 6 000 cells/well). HEK 293 cells transfected with Da151 gp150 env [31], rev and tat 24 h after transfection of HOS-CDC4-Luc cells were layered at increasing densities (30 cells/well –48 000 cells/well in triplicate) onto transfected HOS-CDC4-Luc cells and co-cultured overnight to allow cell fusion. Luciferase activity was determined using the luciferase assay system (Promega, Madison, WI) according to the manufacturer’s instructions and a Veritas luminometer (Promega).

Results

Effects of Amino Acid Substitutions on CCR5 Receptor Signaling

Eight mutant CCR5 receptor constructs that were predicted to be constitutively active were prepared and examined for constitutive and agonist-stimulated IP production in HEK-Gqi cells. Cells expressing the wild type CCR5 receptor displayed increased basal IP production compared to vector-transfected cells (data not shown) and showed enhanced IP production in response to MIP-1β (10−7 M, Fig. 1A, Table 1). All mutants with substitutions of the Thr256Glu residue displayed enhanced basal IP production compared with the wild type receptor (Fig. 1A, Table 1), consistent with a previous report that these mutants are constitutively active [21]. All three mutants showed no further increase in IP production in response to MIP-1β (Fig. 1A, Table 1). Basal IP production in cells transfected with wild type CCR5 or mutant receptors varied with transfection efficiency (compare Figs. 1A and 2A), which resulted in relatively large SEM values (Table 1). The “DRY” motif mutants, Asp162Glu and Asp162Asn, displayed basal IP production that was similar to wild type levels, but displayed decreased IP production in response to MIP-1β (Fig. 1A, Table 1), suggesting that these mutants may be either poorly expressed or uncoupled from G protein activation. The third intracellular loop mutants, Arg361Ala, Arg361Asp and Arg361Glu, displayed basal IP production that was comparable with wild type IP production and decreased MIP-1β-stimulated IP production (Fig. 1A, Table 1), showing that they also were not more constitutively active than wild type CCR5.
Effects of Amino Acid Substitutions on CCR5 Receptor Expression

FACS analysis of cell surface CCR5 expression was used to distinguish changes in receptor expression levels and increased constitutive activity as potential causes of altered IP production in cells transfected with mutant CCR5 constructs. Mean fluorescence was used as a measure of the relative density of receptors expressed on individual cells, while the percentage of cells gated indicates the number of cells expressing more than the threshold level of receptor protein. HEK 293 cells were transiently transfected with CCR5 receptor constructs and the mean fluorescence of grafted wild type-transfected cells was defined as 100% for each experiment. 86% of cells transfected with the wild type were gated (Table 1), indicating high transfection efficiency for HEK 293 cells. The Thr2.56(82)Pro mutant, which showed the highest basal IP production, exhibited mean fluorescence comparable with that of the wild type receptor (Fig. 1B, Table 1). In contrast, the Thr2.56(82)Lys mutant receptor, which also showed increased basal IP production, was poorly expressed, exhibiting low mean fluorescence (6±1.5% of wild type levels, Fig. 1B, Table 1) and a low proportion of cells gated (8±0.5%, Table 1). This low expression combined with a high level of ligand-independent IP production suggests that the Thr2.56(82)Lys mutant receptor is highly constitutively active. The Thr2.56(82)Arg mutant receptor showed intermediate expression levels (Fig. 1B, Table 1). Mutation of Arg6.32(225) to Ala decreased receptor expression, whereas mutation of Asp3.49(125) to Asn or mutation of Arg6.32(225) (Arg6.32(225)Asp, Arg6.32(225)Ala or Arg6.32(225)Gln) had less marked effects on expression of receptor protein (Fig. 1B, Table 1).

Double Amino Acid Substitutions Enhance Expression of Constitutively Active CCR5 Mutants in HEK 293 Cells

As it is well established that efficiency of Env-dependent HIV fusion with host cells is affected by the number of co-receptors expressed on the cell surface [38,39,40,41,42], decreased expression of constitutively active CCR5 receptors is a potential confounding factor in using these mutant receptors to test the role of receptor conformation in Env-directed membrane fusion. Thus, it was necessary to enhance expression of mutant receptors to wild type levels. We initially tried to use the inverse agonist, TAK 779, as a molecular chaperone to increase expression of mutant receptors, but its effects were inconsistent and residual drug was a concern for subsequent analyses. We were also unable to stably express CCR5 constructs in the HOS-CD4-Luc cells. An alternative approach was to combine the mutations that resulted in constitutive activity with the Arg6.32(225)Gln mutation, which previously yielded partial constitutive activity without decreasing receptor expression [22]. Cells transfected with the Thr2.56(82)Lys/Arg6.32(225)Gln double-mutant receptor produced basal IP levels 7.7-fold higher than the wild type receptor and the Thr2.56(82)Pro/Arg6.32(225)Gln mutant receptor displayed basal IP production 9.3-fold higher than that of the wild type receptor (Fig. 2A, Table 1). MIP-1β did not further increase IP production in cells expressing either mutant (Fig. 2A, Table 1). Basal IP production stimulated by the double mutant receptors was higher than the basal IP production of the single mutants and comparable to the maximum MIP-1β-stimulated IP production of the wild type receptor. FACS analysis confirmed that expression of the Thr2.56(82)Lys/Arg6.32(225)Gln double-mutant receptor was increased compared with the Thr2.56(82)Lys receptor (Fig. 2B, Table 1).

Constitutively active GPCRs often have enhanced affinity for agonist ligands [43]. Homologous competition-binding assays were used to assess the affinity of wild type and mutant receptors for the chemokine MIP-1β. In cells expressing the wild type CCR5 receptor, unlabelled MIP-1β displaced the 125I-MIP-1β with an IC50 value of 32.6 nM ±6.5 nM (Fig. 2C). The Thr2.56(82)Lys receptor showed specific binding that was too low for calculation of an IC50 value, consistent with poor expression of this mutant. In contrast, the double mutant, Thr2.56(82)Lys/Arg6.32(225)Gln, displayed total binding comparable to the wild type receptor with an IC50 value of 20.67±4 nM (Fig. 2C). Similarly, both mutants with Pro in position 82, Thr2.56(82)Pro and Thr2.56(82)Pro/Arg6.32(225)Gln, displayed total binding and affinity comparable to the wild type receptor with IC50 values of 31.9±7.4 nM and 30.6±13 nM respectively (Fig. 2C). IC50 values for the mutant receptors were not significantly different from the wild type receptor.

Env-Directed Cell Fusion

To assess the ability of the constitutively active CCR5 mutant receptors to mediate fusion with cells expressing HIV Env protein, cell fusion assays were performed, using dose-response curves in which Env concentration was varied by varying the numbers of
Env-expressing HEK 293 cells, while the concentrations of receptor-expressing HOS-CD4-Luc cells were held constant. This is analogous to standard dose-response experiments with the Env-expressing cells constituting the agonist ligand. Cells expressing the wild type CCR5 receptor fused well with Env-expressing cells (Fig. 3A) and exhibited a mean EC50 value of 14,705 ± 4,591 Env-expressing cells/well (Table 2). Mutant receptors with Lys in position 82, Thr2.56(82)Pro and Thr2.56(82)Pro/Arg6.32(225)Gln mutants, which were expressed at levels similar to the wild type receptor in HEK 293 cells, the Thr2.56(82)Lys mutant, which was poorly expressed, and the double mutant, Thr2.56(82)Arg/Arg6.32(225)Gln, which showed enhanced expression relative to the Thr2.56(82)Lys mutant. Constitutively active mutants with Lys in position 82 showed very low fusion efficiency, but mutants with Pro in position 82 showed good fusion efficiency that was comparable to the wild type receptor.

**Table 1.** IP production and surface expression of wild type and mutant CCR5 receptors.

| CCR5 Receptor Construct | IP Production Basal (CPM) | FACS analysis Mean Fluorescence Intensity (% wild type) | Cells gated (%) |
|-------------------------|--------------------------|----------------------------------------------------|-----------------|
| Wild type               | 2.263 ± 0.417 (9)        | 15.684 ± 1.198 (9)                                 | 100             | 86 ± 0.5 |
| Thr2.56(82)Lys          | 4.783 ± 0.007 (9)        | 4.516 ± 0.915 (9)                                  | 6 ± 1.5         | 8 ± 0.5  |
| Thr2.56(82)Pro          | 9.004 ± 0.3284 ± 0.016 (6) | 12.382 ± 0.161 (6)                               | 92 ± 15         | 47 ± 6.7 |
| Thr2.56(82)Arg          | 2.358 ± 0.373 (7)        | 2.827 ± 0.802 (7)                                 | 19 ± 3          | 51 ± 0.8 |
| Asp3.49(125)Ala         | 1.811 ± 0.368 (8)        | 1.799 ± 0.626 (8)                                 | 11 ± 1.7        | 46 ± 1.8 |
| Asp3.49(125)Asn         | 1.338 ± 0.338 (8)        | 2.827 ± 0.802 (8)                                 | 47 ± 8.5        | 74 ± 0.3 |
| Arg6.32(225)Ala         | 1.438 ± 0.360 (9)        | 6.197 ± 2.550 (9)                                 | 63 ± 10         | 57 ± 11  |
| Arg6.32(225)Asp         | 1.664 ± 0.259 (9)        | 6.446 ± 1.556 (9)                                 | 72 ± 24         | 61 ± 19  |
| Arg6.32(225)Glu         | 1.808 ± 0.418 (9)        | 6.697 ± 2.022 (9)                                 | 43 ± 12         | 69 ± 5.0 |
| 2.56(82)K/R6.32(225)Q   | 14.500 ± 6.321 (9)       | 14.187 ± 4.320 (9)                               | 51 ± 13         | 48 ± 7.5 |
| 2.56(82)P/R6.32(225)Q   | 15.540 ± 6.929 (9)       | 18.038 ± 6.700 (9)                               | 80 ± 21         | 58 ± 7.9 |

*Significantly different from wild type, p < 0.05.

To assess constitutive- and ligand-stimulated IP production, HEK-Gqi cells transiently expressing wild type or mutant CCR5 receptors were labeled with [3H]-inositol and incubated with buffer (Basal) or MIP-1β (10⁻⁷ M, Stimulated). To assess cell surface expression of receptors HEK 293 cells transiently transfected with wild type or mutant CCR5 constructs were incubated with PE-2D7 antibody before FACS analysis. Every experiment included wild type CCR5 and mock transfected cells. Data are means ± SEM calculated from at least three independent experiments performed in duplicate.

doi:10.1371/journal.pone.0054532.t001

**Discussion**

We have investigated the ability of activated CCR5 conformations to mediate HIV Env-directed membrane fusion by generating constitutively active mutant CCR5 receptors. Charge-neutralizing substitutions for Asp3.49(125) in the DRY motif and substitutions of the naturally occurring Arg6.32(225)Gln mutation of CCR5 did not increase constitutive activation of IP signaling. However, substitution of the Thr2.56(82) residue of the TxP motif caused high levels of ligand-independent cellular signaling. The Thr2.56(82)Lys mutation also decreased cell surface CCR5 protein. Severely decreased expression of mutants with Lys, but not Pro, in position 82 suggests that the conformations of the constitutively active mutant receptors differ. Mutant CCR5 receptors with Lys in position 82, which constitutively activated IP signaling, were poor mediators of Env-directed membrane fusion, suggesting that HIV might not enter cells via the activated receptor conformation. However, constitutively active receptors with Pro substituted into the TxP motif mediated Env-directed membrane fusion very efficiently. The differential effects on receptor expression and membrane fusion suggest that Lys and Pro substitutions in position 82 stabilize distinct activated conformations of CCR5 that vary in their ability to mediate Env-dependent membrane fusion.

Constitutively active GPCR mutants are defined by increased ligand-independent (basal) signaling activity. The increased signaling results from an increased population of activated receptor conformations by mutant receptors. Many constitutively active mutants exhibit decreased cell surface expression, which
Figure 2. IP production, expression and competition binding of CCR5 receptors with mutations of Thr2.56(82) and Arg6.32(225).

A, HEK-Gqi cells were transfected with the wild type (■) or mutant CCR5 receptors Thr2.56(82)Lys (●), Thr2.56(82)Pro (▲), Thr2.56(82)Lys/Arg6.32(225)Gln (○) or Thr2.56(82)Pro/Arg6.32(225)Gln (△). Untransfected cells (□) were used as a negative control. Cells pre-labeled with [3H]myo-inositol were incubated with increasing concentrations of MIP-1β. Data are from a single experiment that is representative of at least three independent experiments performed in duplicate.

B, HEK cells were transfected with wild type or mutant CCR5 receptors and stained with PE-2D7 for FACS analysis. Results are mean values ± SEM from at least three independent experiments performed in duplicate.

C, HEK 293 cells were transiently transfected with wild type (■) or mutant CCR5 receptors, Thr2.56(82)Lys (●), Thr2.56(82)Pro (▲), Thr2.56(82)Lys/Arg6.32(225)Gln (○) or Thr2.56(82)Pro/Arg6.32(225)Gln (△) and incubated with 125I-MIP-1β and various concentrations of unlabelled MIP-1β. Cell-bound radioactivity was collected by filtration and counted. Data are from a single experiment, representative of at least three independent experiments performed in triplicate.

doi:10.1371/journal.pone.0054532.g002

Figure 3. Fusion activity of wild type and mutant CCR5 receptors.

A, HOS cells stably expressing CD4 and the luciferase reporter gene were transiently transfected with wild type (■) or mutant CCR5 receptors Thr2.56(82)Lys (●), Thr2.56(82)Pro (▲), Thr2.56(82)Lys/Arg6.32(225)Gln (○) or Thr2.56(82)Pro/Arg6.32(225)Gln (△). CCR5-expressing HOS-CD4-Luc cells were co-cultured overnight with HEK cells transiently expressing tat, rev and Env and luciferase activity was assessed. B, CCR5-expressing HOS-CD4-Luc cells were labeled with PE-2D7 and analyzed by FACS analysis. C, To compare fusion efficiency among mutant receptors that were expressed at different levels the fusion coefficient was derived by dividing the luciferase activity by the mean fluorescence of each construct.

doi:10.1371/journal.pone.0054532.g003
may result from constitutive internalization of the activated receptor, or from increased flexibility of activated receptor conformations that results in protein instability [44,45,46,47].

Inactive and agonist-stabilized activated conformations of CCR5 are likely to be broadly similar to those of other family A GPCRs for which crystal structures are known, including the closely related CXCR4 chemokine receptor [10,48]. Highly conserved amino acid motifs are likely to form intramolecular interactions in CCR5 that are similar to the interactions formed in the inactive and active conformations of GPCRs that have been crystallized [17,49,50].

The “DRY” motif, at the cytosolic end of TMS3, is one of the most conserved sequences among class A GPCRs. According to the “consensus” view of its function, the basic side-chain of Arg3.50 interacts simultaneously with the adjacent acidic Asp3.49 (Glu3.19 in rhodopsin) and with Glu6.30 at the cytosolic end of TMS6, forming an “ionic lock” that stabilizes inactive receptor conformations. In activated receptors the ionic lock is broken and the guanidino group of Arg3.50 moves to interact with Tyr5.58 in TMS5 [17,49,50,51]. The switch function of the DRY motif is supported by charge-neutralizing mutations of Asp3.49 or Arg3.50, which cause constitutive activity in many GPCRs [19,51]. However, our charge-neutralizing mutations of Asp3.49[125] did not cause constitutive activation of IP signaling in CCR5. Decreased expression of the mutant receptors suggests that substitution of Asp3.49[125] decreases receptor protein stability or increases receptor internalization and down-regulation, as has been described for the Arg5.30[126]Asn CCR5 mutant [52]. This suggests that the role of the DRY motif in activation of CCR5 does not comply with the consensus view [51,53].

The Glu6.30 residue in intracellular loop 3 forms part of the ionic lock in rhodopsin, but many GPCRs, including CCR5, have basic residues in position 6.30 [53]. Crystal structures of the inactive CXCR4 chemokine receptor show no interaction between Arg3.50 and Arg6.30 [10,50]. The naturally-occurring Arg6.32[225]Gln CCR5 mutant is partially constitutively active and we hypothesized that Arg6.32[225], which is two residues away from Arg6.30[223], might form alternative interactions that stabilize the inactive CCR5 conformation. Other mutations of Arg6.32[225] did not increase constitutive activity. Decreased expression of these mutants is consistent with the role of basic amino acids in stabilizing membrane-spanning helices [34] although the naturally-occurring Arg6.32[225]Gln mutation did not decrease receptor expression [22]. Furthermore, combining the Thr2.56[82]Lys and Thr2.56[82]Pro mutations with the Arg6.32[225]Gln mutation increased expression of constitutively active mutant CCR5 receptors. The Arg6.32[225]Gln mutation may stabilize a receptor conformation that is less susceptible to internalization or to degradation. The Arg6.32[225]Gln double mutation enhanced expression of constitutively active receptors more effectively in HEK 293 cells than in HOS-CD4-Luc cells. This may result from different receptor trafficking in the two cell lines or it may reflect the generally lower transfection efficiency and receptor expression in HOS-CD4-Luc cells.

Table 2. Env-directed membrane fusion mediated by wild type and mutant CCR5 receptors.

| CCR5 Receptor Construct | Maximum Fusion | Maximum Fusion Efficiency | EC50 |
|-------------------------|----------------|---------------------------|------|
| Wild Type               | 100            | 11.8±2.2                  | 14,705±4,591 |
| γ2.69[82]K              | 4.6±1.7        | 0.84±0.2                  | ND   |
| γ2.69[82]P              | 135±10.9       | 16.5±4.1                  | ND   |
| γ2.69[82]K/R6.32[225]Q | 16.8±3.1       | 1.9±0.4                   | ND   |
| γ2.69[82]P/R6.32[225]Q | 134.8±31.1     | 18.8±5.6                  | 5,545±957 |

*ND, not determined because maximum fusion was too low to allow determination of EC50.

HOS-CD4-Luc cells expressing wild type or mutant CCR5 receptor constructs were co-cultured with increasing concentrations of HEK 293 cells expressing HIV Env and the HIV transactivator, tat, and luciferase activity was measured. Data are means ± SEM of at least five experiments performed in triplicate.

doi:10.1371/journal.pone.0054532.t002
binding affinity, even in the absence of G protein [43]. However, some constitutively active receptors do not exhibit this phenotype [57,59]. We did not find significant changes in IC50 values for MIP-1β binding to constitutively active CCR5 mutants. Arias et al reported similar results for MIP-1β binding, but found that the Thr2.56Lys mutation decreased affinity for the agonist chemokines, MIP-1α and RANTES, whereas the Thr2.56Pro mutation had less effect [21]. Studies with small molecule drugs have suggested that the different chemokine ligands interact with distinct CCR5 conformations [59,60]. The Thr2.56Lys mutation may selectively destabilize the ensembles of CCR5 conformations that preferentially bind MIP-1α and RANTES.

The gp120 subunit of HIV Env is a CCR5 receptor agonist [6,7,8]. However, Env mediates membrane fusion in cells expressing mutant CCR5 receptors that do not support chemokine-stimulated signaling [23,24,25], suggesting that inactive conformations of CCR5 mediate membrane fusion. Furthermore, HIV isolates that are resistant to CCR5 blockers use drug-occupied CCR5 that is stabilized, by the inverse agonist drug, in the inactive conformation to infect cells. We therefore hypothesized that an inactive CCR5 conformation mediates HIV infection and that activated conformations of CCR5 may not support HIV Env-directed membrane fusion.

Consistent with our hypothesis, both of the constitutively active mutants with Lys in position 82 showed low Env-directed membrane fusion efficiency. The decreased fusion may result from decreased expression, as the Thr2.56Lys/Asp3.49Gln double mutation did not fully recover expression in the HOS-CD4-Luc cells used for the fusion assay. Fusion remained reduced than that mediated by wild type CCR5 after correction for receptor expression, but we cannot exclude threshold effects of receptor protein levels. In contrast, constitutively active CCR5 receptors with Pro in position 82 mediated membrane fusion similar to that mediated by wild type CCR5. Our results suggest that CCR5 receptors that constitutively activate IP signaling exist in at least two distinct conformations. One conformation, stabilized by Pro in position 82, supports Env-directed membrane fusion, whereas the other conformation, stabilized by Lys in position 82, does not.

The different capacities of constitutively active CCR5 receptors to mediate membrane fusion may relate to the nature of their constitutive activity. Decreased expression of mutants with Lys in position 82 suggests constitutive receptor phosphorylation and activation of receptor sequestration pathways [61]. Constitutive internalization of CCR5 may target CCR5-Env complexes for degradation and thus inhibit the membrane fusion pathway. Alternatively, receptor conformations that are stabilized by Lys in position 82 may have decreased affinity for HIV Env or decreased ability to induce the fusogenic Env protein configuration that mediates membrane fusion. In terms of the ensemble model of receptor conformation [3,62], mutation of Thr2.56Lys to Lys, may stabilize an ensemble of CCR5 conformations that includes the micro-conformations that activate G proteins and receptor internalization, but not the micro-conformations that induce Env-directed membrane fusion. In contrast, mutation of Thr2.56Pro to Pro appears to stabilize an ensemble of receptor conformations that activate G protein and mediate the co-receptor functions of CCR5, but do not activate internalization (Fig. 4).

Distinct activated conformations of CCR5 with differential abilities to support HIV Env-directed membrane fusion opens the possibility of developing CCR5 ligands that select specific receptor conformations. Indeed, a recent comparison of the CCR5 blockers, TAK 779 and maraviroc, has shown that maraviroc has higher antiviral potency that does not correlate with inverse agonist activity or ability to block gp120 binding. It was suggested that maraviroc may selectively destabilize CCR5 conformations that trigger Env penetration of cell membranes [63]. Furthermore, it has been shown that CCR5 heterodimerizes with the CXCR4 co-receptor and that antagonists specific for one receptor allosterically cross-inhibit ligand binding and agonist function at the other receptor [64]. This raises the potential that CCR5-blocking drugs may be developed to cross-inhibit infection by X4-tropic viruses in cells where both receptors are expressed.

In conclusion, we have shown that charge-neutralizing mutations of the Asp3.49 residue of the DRY motif do not result in constitutive activity of CCR5, confirming that the CCR5 receptor does not conform to the consensus mechanism of receptor activation. We have confirmed that Lys or Pro substitutions for the Thr2.56 residue of the TxP motif cause constitutive activity of CCR5, but we have shown that mutants have distinct properties. Constitutively active mutants with Lys in position 82 show decreased cell surface expression and decreased HIV co-receptor function, whereas mutants with Pro in position 82 were well expressed and fully functional as HIV co-receptors. These distinct properties suggest that the mutations stabilize ensembles of receptor conformations that differ in their ability to induce the fusogenic HIV Env conformation. Our results suggest that drugs that stimulate internalization of CCR5 may effectively inhibit HIV infection, both by decreasing cell surface expression of CCR5 and by stabilizing receptor conformations that inhibit fusion of virus that binds to drug-occupied receptor.

**Acknowledgments**

The HIV-1C env construct pThr.gp150CT [31] was a generous gift from Carolyn Williamson (University of Cape Town). The HIV-1 tat, HIV-1 rev and the pHIV-1LTR-Luc reporter construct were generously provided by...
References

1. Oppermann EY (2004) Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal 16: 1201–1210.

2. Lederman MM, Fein-Nicholson A, Cho M, Mosier D (2006) Biology of CCR5 and its role in HIV infection and treatment. JAMA 296: 813–826.

3. Kenakin T (2002) Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42: 349–379.

4. Depri X, Kobilka BK (2010) Energy landscapes as a tool to integrate GPCR structure, dynamics, and function. Physiology (Bethesda) 25: 293–303.

5. Mack M, Luckow B, Nelson PJ, Giah K, Simmons G, et al. (1998) Aminoacyl-tRNA:RANSES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infection. Exp Med 197: 1215–1224.

6. Freedman BD, Liu QH, Del Corso M, Collman RG (2003) HIV-1 gp120 chemokine receptor- mediating signal in human macrophages. Immunol Rev 267: 261–276.

7. Weizman D, Rabin RL, Arhos J, Rubbert A, Dybdal M, et al. (1997) Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature 389: 981–985.

8. Wu Y, Yoder A (2009) Chemokine coreceptor signaling in HIV-1 infection and pathogenesis. Pharmacol Rev 61: 387–437.

9. Palczewski K, Kumasaka T, Hori T, Belenke CA, Motoshima H, et al. (2000) Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289: 739–745.

10. Wu B, Chávez MD, Della G, Liu W, et al. (2010) Structures of the CCR4-adrenergic GPCR complex with small-molecule and cyclic peptide antagonists. Science 330: 1066–1071.

11. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, et al. (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318: 1256–1260.

12. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, et al. (2007) Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450: 367–377.

13. Choi HW, Kim YJ, Park JH, Morinimami T, Pai EF, et al. (2011) Crystal structure of metahorpholin II. Nature 471: 651–655.

14. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, et al. (2000) Crystal structure of opsin in its G-protein-interacting conformation. Nature 455: 497–502.

15. Rasmussen SG, DeVeere BT, Zou Y, Kruse AC, Chung KY, et al. (2011) Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 474: 549–555.

16. Hofmann KP, Scheerer P, Hildebrand PW, Choi HW, Park JH, et al. (2009) A G protein-coupled receptor at work: the rhodopsin model. Trends Biochem Sci 34: 540–552.

17. Ahuja S, Smith SO (2009) Multiple switches in G protein-coupled receptor ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol Sci 30: 494–502.

18. Nygaard R, Frimurer TM, Holst B, Rosenkilde MM, Schwartz TW (2009) Structural instability of the histamine H2 receptor. Mol Pharmacol 57: 890–894.

19. Weissman D, Rabin RL, Arthos J, Rubbert A, Dybul M, et al. (1997) Mutations in the DRY motif affect constitutive activity and pharmacological properties of the gamma2 subunit of the G protein gamma2 gamma2 beta2 receptor. J Biol Chem 272: 2054–2057.

20. Gether U, Ballesteros JA, Seifert R, Sanders-Bush E, Weinstein H, et al. (1997) Characterization of G protein-coupled receptors. Curr Opin Struct Biol 7: 432–440.

21. Doms RW (2000) Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. Virology 276: 229–237.

22. Lin YL, Mettling C, Portales P, Reynes J, Clot J, et al. (2002) Cell surface CCR5 is a determinant of virus load in infected subjects with human immunodeficiency virus type 1. J Infect Dis 181: 927–929.

23. Platt EJ, Welayo K, Kuhlmann SE, Chesebro B, Kabat D (1998) Effects of CCR5 and C4D cell surface concentrations on infections by macrophage-tropic isolates of human immunodeficiency virus type 1. J Virol 72: 2033–2040.

24. Gaertner H, Cerini F, Escola JM, Karsan G, Melotti A, et al. (2000) Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proc Natl Acad Sci U S A 107: 17706–17711.

25. Doms RW (2000) Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. Virology 276: 229–237.

26. Lin YL, Mettling C, Portales P, Reynes J, Clot J, et al. (2002) Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. Proc Natl Acad Sci U S A 99: 15390–15395.

27. Rovati GE, Capra V, Neubig RR (2007) The highly conserved DRY motif of G protein-coupled receptors: The GnRH Receptor. Methods in Neuroscience 25: 145–162.

28. Rasmussen CA, Fromme BJ, Davidson JS, Miller RP (1998) A high affinity gonadotropin-releasing hormone (GnRH) tracer, radioiodinated at position 6, facilitates analysis of mutant GnRH receptors. Endocrinology 139: 4111–4119.

29. Fromme BJ, Coesmee M, Van Der Watt P, Chan MC, Serming KL, et al. (2008) High-affinity binding of southern African HIV type 1 subtype C envelope protein, gp120, to the CCR5 coreceptor. AIDS Res Hum Retroviruses 24: 1527–1536.

30. Reyes J, Portales P, Segondy M, Ballat V, Andre P, et al. (2000) CD4+ T cell surface CCR5 density as a determining factor of virus load in infected persons with human immunodeficiency virus type 1. J Biol Chem 275: 2507–2509.

31. Millar RP, Davidson J, Flanagan C, Wakefield I (1995) Ligand Binding and Second-Messenger Assays in Cholesterol/G11-Gated Neuropeptide Receptors: The GnRH Receptor. Methods in Neuroscience 25: 145–162.

32. Gether U, Ballesteros JA, Seifert R, Sanders-Bush E, Weinstein H, et al. (1997) Structural instability of a constitutively active G protein-coupled receptor. Trends Pharmacol Sci 18: 468–474.

33. Deupi X, Kobilka BK (2010) Energy landscapes as a tool to integrate GPCR functions of the chemokine receptor CCR5. J Biol Chem 285: 17803–17810.

34. Ballesteros J, Weinstein W (1995) Integrated methods for the construction of an allosteric Model of Maraviroc Binding to CC Chemokine Receptor 5 (CCR5). J Biol Chem 280: 17803–17810.

35. Alewijnse AE, Timmerman H, Jacobs EH, Smit MJ, Roovers E, et al. (2000) The effect of mutations in the DRY motif on the constitutive activity and pharmacological properties of the gamma2 subunit of the G protein gamma2 gamma2 beta2 receptor. J Biol Chem 275: 2507–2509.

36. Alewijnse AE, Timmerman H, Jacobs EH, Smitt MJ, Roovers E, et al. (2000) The effect of mutations in the DRY motif on the constitutive activity and structural instability of the histamine H2 receptor. Mol Pharmacol 57: 1534–1544.

37. Garcia-Perez J, Rueda P, Alcami J, Rogman D, Arenzana-Seisdedos F, et al. (2011) Allosteric Model of Maraviroc Binding to CC Chemokine Receptor 5 (CCR5). J Biol Chem 286: 35409–35421.

38. Depri X, Standfuss J (2011) Structural insights into agonist-induced activation of constitutively active G protein-coupled receptors. Curr Opin Struct Biol 21: 541–551.

39. Szakalowska B, Latek D, Yuan S, Ghoshdastider U, Debinski A, et al. (2012) Action of molecular switches in GPCRs-theoretical and experimental studies. Curr Med Chem 19: 1090–1109.

40. Rotavi GE, Cagara V, Neubig RR (2007) The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state. Mol Pharmacol 71: 959–964.

Author Contributions

Conceived and designed the experiments: AdV CAF. Performed the experiments: AdV CAF. Analyzed the data: AdV CAF. Contributed reagents/materials/analysis tools: ATF MCC. Wrote the paper: AdV CAF.
52. Lagane B, Ballet S, Planchenaud T, Balabanian K, Le Foul E, et al. (2005) Mutation of the DRY motif reveals different structural requirements for the CC chemokine receptor 5-mediated signaling and receptor endocytosis. Mol Pharmacol 67: 1966–1976.

53. Springael JY, de Poorter C, Derqui X, Van Durme J, Pardo L, et al. (2007) The activation mechanism of chemokine receptor CCR5 involves common structural changes but a different network of interhelical interactions relative to rhodopsin. Cell Signal 19: 1446–1456.

54. Dalley RE. (1996) Positively charged residues are important determinants of membrane protein topology. Trends Biochem Sci 15: 253–257.

55. Govaerts C, Bondue A, Springael JY, Olivella M, Derqui X, et al. (2003) Activation of CCR5 by chemokines involves an aromatic cluster between transmembrane helices 2 and 3. J Biol Chem 278: 18992–19003.

56. Pei G, Samama P, Lohse M, Wang M, Codina J, et al. (1994) A constitutively active mutant beta 2-adrenergic receptor is constitutively desensitized and phosphorylated. Proc Natl Acad Sci U S A 91: 2699–2702.

57. Zhang WB, Navenot JM, Haribabu B, Tamamura H, Hiramatu K, et al. (2002) A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40–4C are weak partial agonists. J Biol Chem 277: 24515–24521.

58. Beinhorn M, Ren Y, Blaker M, Chen C, Kopin AS. (2004) Ligand function at constitutively active receptor mutants is affected by two distinct yet interacting mechanisms. Mol Pharmacol 65: 753–760.

59. Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, et al. (2004) Spiroidiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 78: 8654–8662.

60. Watson C, Jenkinson S, Kazmerski W, Kenakin T. (2005) The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 67: 1268–1292.

61. Parnot C, Miseray-Lenkei S, Bardin S, Corvol P, Clauser E. (2002) Lessons from constitutively active mutants of G protein-coupled receptors. Trends Endocrinol Metab 13: 336–343.

62. Vaidheli N, Kenakin T. (2010) The role of conformational ensembles of seven transmembrane receptors in functional selectivity. Curr Opin Pharmacol 10: 775–781.

63. Garcia-Perez J, Rueda P, Staropoli I, Kellenberger E, Alcami J, et al. (2011) New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection. J Biol Chem 286: 4978–4990.

64. Sohy D, Yano H, de Nadai P, Urizar E, Guillabert A, et al. (2009) Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of “selective” antagonists. J Biol Chem 284: 31270–31279.